(Total Views: 622)
Posted On: 01/10/2025 8:39:05 AM
Post# of 154569
Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) based on phase 1 results.
Under the terms of the agreement Mediar will receive a combined $99 million, which is inclusive of an upfront payment and near-term milestones. Mediar may receive up to an additional $687 million in potential downstream development and commercialization milestones. Additionally, Mediar is eligible to receive high-single to low-double digit royalty payments and net sales milestones based on potential future product sales.
Perhaps a deal like this sometime in our future...
https://www.mediartx.com/wp-content/uploads/2...-10-25.pdf
https://www.mediartx.com/wp-content/uploads/2...or_IPF.pdf
Under the terms of the agreement Mediar will receive a combined $99 million, which is inclusive of an upfront payment and near-term milestones. Mediar may receive up to an additional $687 million in potential downstream development and commercialization milestones. Additionally, Mediar is eligible to receive high-single to low-double digit royalty payments and net sales milestones based on potential future product sales.
Perhaps a deal like this sometime in our future...
https://www.mediartx.com/wp-content/uploads/2...-10-25.pdf
https://www.mediartx.com/wp-content/uploads/2...or_IPF.pdf
(7)
(0)
